Subcutaneous formulation of Tecentriq demonstrates positive phase III results

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq (atezolizumab) showed non-inferior levels of Tecentriq in the blood, when injected subcutaneously, compared with intravenous infusion.

Tecentriq is sponsored by Genentech. 

The study included cancer immunotherapy-naïve patients with locally advanced or metastatic NSCLC for whom prior platinum therapy has failed. 

The safety profile of the subcutaneous formulation was consistent with that of IV Tecentriq.

Subcutaneous administration would reduce the time patients spend receiving treatment from 30-60 minutes with IV infusion to only 3-8 minutes. 

Genentech will share detailed findings of the IMscin001 study at an upcoming medical meeting and submit them for regulatory approval to health authorities globally, including FDA and European Medicines Agency.

Table of Contents

YOU MAY BE INTERESTED IN

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 
Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked. A study led by researchers at Washington University School of Medicine in St. Louis takes a deep dive into inherited cancer mutations measured in a healthy blood sample and reports how those mutations might take a toll on the body’s cells starting at birth, perhaps predisposing a person to develop cancers at various stages of life.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login